← Search & browse all drugs

naphazoline

S01GA01

Forms & Strengths

Ophthalmic solution 0.05% (1 mg/mL)
Ophthalmic solution 0.025% (0.5 mg/mL)
Nasal spray solution 0.05% (1 mg/mL)

Adult Dosing

Ocular: 1‑2 drops in each affected eye every 4‑6 h; max 8 drops/24 h
Nasal: 1‑2 sprays per nostril every 4‑6 h; max 3‑4 doses/24 h

Pediatric Dosing

Ocular: children ≥ 12 yr same as adult; 2‑12 yr: 1 drop per eye q6‑8 h, max 4 drops/24 h; <2 yr: not recommended

Indications

Relief of transient ocular redness due to minor irritation or allergic conjunctivitis
Temporary nasal congestion due to common cold, allergic rhinitis, or sinusitis

Mechanism of Action

Selective α1‑adrenergic agonist causing vasoconstriction of conjunctival and nasal mucosal vessels, reducing hyperemia and edema

Contraindications

Narrow‑angle (angle‑closure) glaucoma
Severe hypertension or uncontrolled cardiovascular disease
Known hypersensitivity to naphazoline or formulation excipients

Adverse Reactions

Transient ocular burning or stinging
Dryness or foreign‑body sensation in eye
Rebound hyperemia/tachyphylaxis with prolonged use (>3‑5 days)
Headache, elevated systemic blood pressure, palpitations (rare)
Nasal irritation, dryness, epistaxis

Drug Interactions

Concurrent systemic sympathomimetics or MAO inhibitors may potentiate hypertensive effects
Antihypertensive agents (β‑blockers, ACE‑inhibitors) may have reduced efficacy
Other topical vasoconstrictors increase risk of rebound congestion/hyperemia

Curated Content: Needs Vetting Before Put to Clinical Use